| Date | Time | Source | Headline | Symbol | Company |
| 04/06/2011 | 3:18PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:39PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:39PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 4:38PM | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/24/2011 | 7:35AM | Marketwired | Healthcare Acquisition Activity on the Rise as Key Patents Run Out | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/16/2011 | 8:00AM | PR Newswire (US) | Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/14/2011 | 10:04AM | PR Newswire (US) | Zacks Analyst Blog Highlights: Amylin Pharmaceuticals, Eli Lilly and Company, Alkermes, Novo Nordisk and The Dow Chemical | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/10/2011 | 10:20AM | PR Newswire (US) | Exenatide Once Monthly Showed Positive Results in Phase 2 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/10/2011 | 8:05AM | Business Wire | Exenatide Once Monthly Showed Positive Results in Phase 2 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/10/2011 | 8:00AM | PR Newswire (US) | Exenatide Once Monthly Showed Positive Results in Phase 2 Study | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/09/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/04/2011 | 5:06PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 12:57PM | Dow Jones News | 2nd UPDATE: Lilly, Amylin, Alkermes Diabetes Drug Fails Comparison | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 10:25AM | Dow Jones News | CORRECT: Lilly, Amylin, Alkermes Diabetes Treatment Misses Primary Endpoints | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 9:59AM | Dow Jones News | UPDATE: Lilly, Amylin, Alkermes Diabetes Drug Fails In Comparison | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 9:01AM | Dow Jones News | Lilly, Amylin, Alkermes Diabetes Treatment Misses Primary Endpoints | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 8:13AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 8:05AM | Business Wire | DURATION-6 Top-Line Study Results Announced | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/03/2011 | 8:00AM | PR Newswire (US) | DURATION-6 Top-Line Study Results Announced | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 02/25/2011 | 4:52PM | Edgar (US Regulatory) | Annual Report (10-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 02/17/2011 | 9:30AM | PR Newswire (US) | Zacks Analyst Blog Highlights: Penske Automotive Group, Alkermes, Johnson & Johnson, Eli Lilly and Company and Amylin Pharmaceut | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 02/15/2011 | 5:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |